Vertical: HealthcareBase Year: 202355 Sections
Market Size (2023)
$28.31B
Projected (2032)
$98.35B
CAGR (2019–2032)
12.9%
Key Players
100+
This report covers Biosimilar Market with forecasts from 2019 to 2032. 100 key companies are profiled.
The Biosimilar Market market is projected to grow at a CAGR of 12.9% from 2019 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansINTRODUCTION
The growing incidence of cancer and rare disorders, along with the increasing launch of biosimilars, is driving the global biosimilar market. Furthermore, rising healthcare costs are boosting market growth. However, government initiatives, regulatory support, and the increasing adoption of biosimilars in emerging markets are expected to restrain market expansion. Despite these barriers, expansion in emerging markets, along with partnerships and collaborations, is expected to create significant growth opportunities for the market in the future.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2023
Historical Period
2019 – 2022
Forecast Period
2024 – 2032
Primary Interviews
150+
Historical data (2019–2023) and forecast period (2023–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMichael Porter's Five Forces model is a framework to study the global biosimilar market. Strategic business managers trying to gain an edge over competing firms in the global biosimilar market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the Global biosimilar market have been broken down and analysed.
PORTER'S FIVE FORCES ANALYSIs: Global biosimilar market
Threat of New Entrants
The threat of new entrants in the global biosimilar market is moderate to high. While biosimilars present a significant opportunity due to the increasing demand for cost-effective biologic treatments, the barriers to entry are substantial. These include high R&D costs, the need for regulatory approvals, and the complexity of manufacturing biologics. Additionally, established pharmaceutical companies with strong brand loyalty and market share dominate the market, making it challenging for new entrants to compete. However, advancements in technology and partnerships with established firms can help reduce entry barriers and provide new players with a competitive edge.
BARGAINING POWER OF SUPPLIERS
The bargaining power of suppliers in the biosimilar market is relatively moderate. The biosimilar manufacturing process requires specialized raw materials, including cell lines, bioreactors, and advanced production technologies. As the number of suppliers in the biotechnology and pharmaceutical sectors increases, competition among suppliers can reduce their bargaining power. However, the reliance on high-quality, specialized materials and the few suppliers capable of meeting regulatory standards can give certain suppliers more leverage in pricing and terms.
Threat of Substitutes
The threat of substitutes in the biosimilar market is moderate. While biosimilars are designed to be cost-effective alternatives to original biologics, there are still concerns about their safety and efficacy, which may limit their widespread adoption in some regions. Additionally, alternative treatments like small-molecule drugs or innovative biologics (such as gene therapies or cell-based therapies) could provide substitutes in certain therapeutic areas. However, the growing demand for affordable biologics positions biosimilars as a valuable option, reducing the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of buyers in the global biosimilar market is high, particularly due to the increasing pressure to lower healthcare costs. Government health agencies, insurance providers, and large healthcare providers often have significant negotiating power when purchasing biosimilars, as they seek cost-effective solutions for their patients. In addition, patients are becoming more aware of biosimilars as affordable alternatives, which further amplifies the bargaining power of buyers. The availability of multiple biosimilars for the same reference biologic also increases buyer power by fostering competition.
Intensity of Rivalry
The intensity of rivalry in the biosimilar market is high. As more biosimilar products enter the market, competition among companies increases, especially among firms aiming to replicate the same reference biologic. Established companies with existing portfolios of biologics and generics are expanding their biosimilar offerings, while new companies try to capture market share. Furthermore, companies are competing on pricing, product differentiation, and regulatory approvals, all of which contribute to the intensity of rivalry. While growth opportunities exist in emerging markets, companies must navigate competitive pressures in developed markets where regulatory hurdles and pricing wars are prevalent.
IMPACT OF COVID-19 on GLOBAL BIOSIMILAR MARKET
The COVID-19 pandemic had a profound and complex impact on the global biosimilar market, presenting both significant challenges and a range of new opportunities. Initially, the pandemic disrupted global supply chains, leading to severe shortages and delays in the production of raw materials essential for biosimilar manufacturing. This disruption was compounded by a slowdown in clinical trials as many ongoing studies were halted or delayed, as healthcare resources were redirected toward treating COVID-19 patients. Regulatory agencies, already overwhelmed by the crisis, faced delays in reviewing biosimilar applications and approvals. As a result, many biosimilar manufacturers found it difficult to maintain consistent production and meet market demand, causing potential setbacks in the launch of new biosimilars and the expansion of existing product portfolios. Healthcare systems worldwide were stretched to their limits, which led to prioritization of critical care, delaying patient access to non-COVID-related treatments, including routine biologic therapies. The challenge of maintaining continuity in patient access to essential treatments, including biosimilars, became a critical issue during the pandemic.
However, the pandemic also underscored the urgent need for affordable, accessible healthcare solutions. With the economic strain of the global health crisis, governments and healthcare providers were faced with rising healthcare costs, heightening the demand for cost-effective alternatives to expensive biologics. This amplified the market potential for biosimilars, as they offered a means to maintain treatment quality while alleviating budgetary pressures. The shift towards more affordable biologics was accelerated by the increased emphasis on reducing healthcare expenditures and expanding patient access to essential medications. Furthermore, the pandemic spurred the rapid adoption of digital health technologies, including telemedicine and remote patient monitoring. This transition indirectly benefited the biosimilar market by enabling more widespread use of cost-effective treatments in virtual healthcare settings. Patients were increasingly able to access biosimilars through telemedicine platforms, which contributed to the growing demand for these therapies, especially in remote and underserved areas.
Looking ahead, the pandemic is likely to have a lasting impact on the biosimilar market. The lessons learned about the importance of affordable treatment options, coupled with the increased reliance on digital healthcare, are expected to drive sustained growth in the biosimilar sector. As healthcare systems around the world continue to seek ways to balance cost containment with high-quality care, biosimilars are poised to play a central role in meeting these dual objectives. This shift in focus will likely result in even greater adoption and investment in biosimilars, as stakeholders continue to prioritize both economic sustainability and patient access to essential therapies. The long-term effect of the pandemic could thus be a transformation in the global healthcare landscape, where biosimilars are more integrated into treatment protocols and recognized as a critical component in the fight against both rising healthcare costs and access inequities..
Market estimates by geography (2032)
InsightROW leads with $1.00B by 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2023 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $0.17M | $0.21M | $0.23M | 2.4% | 0% |
| Europe | $0.75M | $0.69M | $0.64M | -1.3% | 0% |
| Asia-Pacific | $0.06M | $0.09M | $0.12M | 5.6% | 0% |
| ROW | $378.69M | $729.84M | $1.00B | 7.8% | 100% |
| Middle East and Africa | $0.40M | $0.42M | $0.43M | 0.7% | 0% |
| South America | $0.60M | $0.58M | $0.57M | -0.5% | 0% |
| Total | $380.67M | $731.82M | $1.01B | 12.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$98.35B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Oncology | $44.18B | 14.1% | 45% |
| Blood Disorders | $27.34B | 12.2% | 28% |
| Others | $17.28B | 11.5% | 18% |
| Autoimmune Diseases | $7.54B | 13.2% | 8% |
| Infectious Diseases | $2.01B | 10.4% | 2% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Biosimilar Market covering market dynamics, competitive landscape, and strategic outlook.
The Biosimilar Market market is projected to reach $98.35B by 2032, growing at 12.9% CAGR. The Oncology segment holds the largest share.
INTRODUCTION
The growing incidence of cancer and rare disorders, along with the increasing launch of biosimilars, is driving the global biosimilar market. Furthermore, rising healthcare costs are boosting market growth. However, government initiatives, regulatory support, and the increasing adoption of biosimilars in emerging markets are expected to restrain market expansion. Despite these barriers, expansion in emerging markets, along with partnerships and collaborations, is expected to create significant growth opportunities for the market in the future.
Growing incidences of Cancer and rare disorders
The growing incidences of cancer and rare disorders are playing a pivotal role in boosting the growth of the global biosimilar market. As the prevalence of these complex and often life-threatening conditions continues to rise, there is an increasing demand for effective and affordable treatment options. Biosimilars, which are highly similar to reference biologic drugs, provide a cost-efficient alternative to expensive therapies, making critical treatments more accessible to patients. For instance, according to the International Agency for Research on Cancer, there were cancer cases of nearly 9,826,539 in Asia, 4,471,422 in Europe, 2,673 174 in Northern America, 1,551,060 in Latin America and the Caribbean, 1,185,216 in Africa, and 269 088 in Oceania cancer cases of both genders in 2022. Furthermore, India also reported increasing incidences of cancer, which is contributing to the growth of the global biosimilar market. As per the International Agency for Research on Cancer, there were 192,020 breast cancer cases, 143,759 lip, oral cavity, 127,526 cervix uteri, 81,748 lung, 70,637 oesophagus, 70,038 colorectum, and 727,588 cancer cases of others. These increased cases of cancer are increasing the demand for biosimilar by healthcare providers and patients which leads to the frequent launches of biosimilar.
For instance, in May 2023, The FDA has granted approval to Yuflyma, the ninth biosimilar of adalimumab. Celltrion USA recently announced that Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100mg/mL) version of Humira, has been approved for use. This biosimilar is authorized to treat eight inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. Moreover, as per the American Lung Association, there were about 30,000 people with cystic fibrosis in the US and nearly 70,000 people worldwide in 2022. Also, in April 2024, the Centers for Disease Control and Prevention reported that nearly 6,000 babies born with Down syndrome in the United States.
Furthermore, the expiration of patents for several high-cost biologics has further accelerated the development and approval of biosimilars, enabling healthcare systems to reduce costs without compromising on quality. This trend is driving the rapid expansion of the biosimilar market, as it addresses the dual challenges of rising disease burden and the need for sustainable healthcare solutions.
Thus, the increasing incidences of cancer and rare disorders across the globe and rising innovative product launches to treat these diseases are boosting the growth of the market.
Increasing launch of Biosimilars
The increasing launch of biosimilars is significantly bolstering the growth of the global biosimilar market, as pharmaceutical companies and regulatory bodies actively work to expand the availability of these cost-effective alternatives to biologic drugs. With the expiration of patents for several blockbuster biologics, manufacturers are seizing the opportunity to develop and introduce biosimilars across a wide range of therapeutic areas, including oncology, autoimmune diseases, and chronic conditions.
May 2024: Teva Pharmaceuticals and Alvotech launched of SIMLANDI (adalimumab-ryvk) injection in the U.S. as the first interchangeable, high-concentration, citrate-free biosimilar to Humira. This biosimilar is designed to treat a range of conditions, including adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.
July 2024: Sandoz launched of its high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz) in the United States, marking its entry into the US immunology market. This citrate-free HCF biosimilar offers US patients a reduced injection volume. As one of the few adalimumab HCF biosimilars approved in the US, Hyrimoz HCF enhances access for millions of individuals with serious inflammatory conditions.
October 2023: The FDA approved Celltrion USA's Zymfentra (infliximab-dyyb), the world’s first and only subcutaneous infliximab product. Approved as a novel drug, Zymfentra is developed based on Remicade, the reference intravenous infliximab. It is specifically approved for the treatment of adults with moderate to severe inflammatory bowel disease (IBD), which includes both ulcerative colitis (UC) and Crohn’s disease (CD), following prior treatment with an intravenously administered infliximab product.
June 2022: The FDA has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, for the treatment of adults with moderate to severe rheumatoid arthritis (RA) in combination with methotrexate, specifically for those who haven't responded adequately to TNF antagonist therapies. RIABNI is also approved for treating Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA).
December 2019: Daiichi Sankyo has announced the launch of its bevacizumab biosimilar for intravenous drip infusions in Japan. The product, developed in collaboration with Amgen, is available in 100 mg and 400 mg doses. It is a biosimilar to the anti-VEGF humanized monoclonal antibody bevacizumab, approved in Japan on September 20, 2019, for treating unresectable advanced or recurrent colorectal cancer. This launch marks a significant step in providing cost-effective cancer treatment options in Japan.
April 2020: Merck launched of ONTRUZANT (trastuzumab-dttb), a biosimilar to Herceptin® (trastuzumab). Available in 150 mg single-dose vials and 420 mg multiple-dose vials, ONTRUZANT is priced at approximately USD 1,325 for the 150 mg vial and USD 3,709 for the 420 mg vial, offering a 15% discount compared to Herceptin’s list price.
Regulatory agencies, such as the FDA and EMA, have streamlined approval processes, encouraging more companies to enter the market and accelerating the pace of biosimilar launches. This surge in availability is driving competition, reducing treatment costs, and improving patient access to essential therapies. Additionally, healthcare systems worldwide are increasingly adopting biosimilars to alleviate financial burdens while maintaining high standards of care. As a result, the growing pipeline and commercialization of biosimilars are playing a crucial role in expanding the global biosimilar market, making it a cornerstone of modern healthcare innovation.
Rising healthcare costs
Rising healthcare costs have become a significant concern worldwide, driven by factors such as aging populations, increasing prevalence of chronic diseases, and the high prices of innovative biologic drugs. As governments, insurers, and patients grapple with the financial burden, there is a growing demand for cost-effective alternatives that do not compromise on quality or efficacy. This has spurred the burgeoning growth of the global biosimilar market, as biosimilars offer a more affordable option compared to their reference biologics, often at a fraction of the cost. By providing similar therapeutic benefits, biosimilars are increasingly being adopted across various therapeutic areas, including oncology, autoimmune diseases, and diabetes. Regulatory support, coupled with advancements in biomanufacturing technologies, has further accelerated their development and market penetration. As healthcare systems prioritize cost containment without sacrificing patient outcomes, biosimilars are poised to play a pivotal role in shaping a more sustainable and accessible healthcare landscape.
Expansion in emerging markets is creating significant opportunities for the biosimilars market, driven by the increasing demand for affordable healthcare solutions and the growing burden of chronic diseases in these regions. Countries in Asia, Latin America, the Middle East, and Africa are witnessing rapid population growth, urbanization, and improvements in healthcare infrastructure, which are expanding access to advanced treatments. As these regions face rising prevalence of conditions like cancer, diabetes, and autoimmune disorders, the high cost of originator biologics often limits patient access, creating a strong demand for cost-effective biosimilars. Governments and healthcare systems in emerging markets are increasingly adopting supportive regulatory frameworks and policies to encourage biosimilar adoption, further accelerating market growth. Additionally, local manufacturing initiatives and partnerships between global biosimilar developers and regional players are enhancing production capabilities and distribution networks. This expansion not only addresses unmet medical needs but also positions emerging markets as key growth drivers for the global biosimilars industry, offering immense potential for market penetration and improved patient outcomes. Partnerships and collaborations are playing a crucial role in driving growth and innovation in the global biosimilar market.
By bringing together biopharmaceutical companies, research institutions, and regulatory bodies, these alliances enable the pooling of expertise, resources, and technologies necessary to accelerate the development and commercialization of biosimilars. Collaborative efforts help streamline the complex and costly approval processes, foster innovation, and reduce time to market. ▪ January 2025: Teva Pharmaceuticals formed a strategic collaboration with Klinge Biopharma and Formycon to semi- exclusively commercialize FYB203, a biosimilar candidate to Eylea (aflibercept), in Europe (excluding Italy) and Israel. This partnership builds on their successful collaboration ith ormycon’s biosimilar YB to ucentis ranibizumab in Europe. The agreement strengthens Teva's biosimilars portfolio and aligns with its Pivot to Growth strategy, combinin Teva’s commercial e pertise ith ormycon’s development capabilities Klin e holds the e clusive lobal commercialization rights for FYB203. ▪ October 2024: Teva Pharmaceuticals and mAbxience expanded their strategic partnership to include the development of an additional oncology biosimilar candidate targeting anti PD-1. This new global licensing agreement marks the second collaboration between the companies, following their initial partnership in April 2024. The expanded agreement supports Teva's Pivot to Growth strategy and strengthens its biosimilar portfolio.
Both companies reaffirmed their commitment to providing high-quality, affordable treatments to patients worldwide. ▪ March 2024: Biocon Biologics announced a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India. This partnership aligned with Biocon Biolo ics’ strate y to levera e its legacy business in branded formulations and extended its existing collaboration with Eris, which had started in December 2023 for Biocon's Nephrology and Dermatology products. ▪ June 2021: Teva Pharmaceuticals and Bioeq AG formed strategic partnership for the exclusive commercialization of FYB201, a biosimilar candidate to Lucentis (ranibizumab). This agreement covers the marketing of FYB201 in Europe, Canada, Israel, and New Zealand. The collaboration aims to bring this ophthalmology biosimilar to key global markets. Additionally, partnerships with established pharmaceutical companies provide biosimilar manufacturers with access to broader distribution networks, funding, and market insights. This cooperation not only helps meet the rising global demand for affordable biologic therapies but also strengthens market competition, ultimately benefiting patients by increasing access to high-quality, cost- effective treatments.
Regulatory and approval barriers
Regulatory and approval barriers are significant impediments to the growth of the global biosimilars market, despite its potential to provide cost-effective alternatives to biologic drugs. The development of biosimilars requires rigorous and costly processes to demonstrate similarity to reference biologics in terms of safety, efficacy, and quality. According to a report by the Generics and Biosimilars Initiative, the average cost of developing a biosimilar range from 100 million to 300 million, with clinical trials alone accounting for a substantial portion of this expense. Additionally, regulatory requirements vary widely across regions, creating inconsistencies and delays. For example, while the FDA and EMA have established relatively streamlined pathways, other regions, such as parts of Asia and Latin America, lack clear or harmonized guidelines, leading to prolonged approval timelines. A 2021 study by the RAND Corporation found that biosimilars in the U.S. take an average of 7 to 8 years to reach the market after patent expiration, compared to 3 to 5 years for traditional generics. Furthermore, legal challenges and patent litigations from originator companies often delay market entry, with over 70% of biosimilar launches in the U.S. facing such disputes, as reported by the Association for Accessible Medicines. These barriers not only increase development costs but also limit the timely availability of biosimilars, restraining the global market's growth despite the rising demand for affordable biologic therapies.
Limited Reimbursement and Market Access
Limited reimbursement and market access policies are playing a pivotal role in driving the growth of the global biosimilar market. As healthcare systems worldwide face increasing cost pressures, biosimilars—which are highly similar to already approved biologic drugs but offered at lower prices—are becoming a preferred alternative to expensive originator biologics. Limited reimbursement policies, which often restrict coverage to the most cost-effective treatments, are encouraging the adoption of biosimilars by making them more financially accessible to patients and healthcare providers. Additionally, streamlined market access pathways, such as expedited regulatory approvals and supportive frameworks in regions like Europe and the U.S., are further accelerating the entry of biosimilars into the market. This combination of cost containment strategies and favorable regulatory environments is fostering competition, reducing healthcare expenditures, and expanding patient access to essential therapies, thereby fueling the rapid growth of the global biosimilar market.
Expansion in emerging markets is creating significant opportunities for the biosimilars market, driven by the increasing demand for affordable healthcare solutions and the growing burden of chronic diseases in these regions. Countries in Asia, Latin America, the Middle East, and Africa are witnessing rapid population growth, urbanization, and improvements in healthcare infrastructure, which are expanding access to advanced treatments. As these regions face rising prevalence of conditions like cancer, diabetes, and autoimmune disorders, the high cost of originator biologics often limits patient access, creating a strong demand for cost-effective biosimilars. Governments and healthcare systems in emerging markets are increasingly adopting supportive regulatory frameworks and policies to encourage biosimilar adoption, further accelerating market growth. Additionally, local manufacturing initiatives and partnerships between global biosimilar developers and regional players are enhancing production capabilities and distribution networks. This expansion not only addresses unmet medical needs but also positions emerging markets as key growth drivers for the global biosimilars industry, offering immense potential for market penetration and improved patient outcomes.
Partnerships and Collaborations
Partnerships and collaborations are playing a crucial role in driving growth and innovation in the global biosimilar market. By bringing together biopharmaceutical companies, research institutions, and regulatory bodies, these alliances enable the pooling of expertise, resources, and technologies necessary to accelerate the development and commercialization of biosimilars. Collaborative efforts help streamline the complex and costly approval processes, foster innovation, and reduce time to market.
January 2025: Teva Pharmaceuticals formed a strategic collaboration with Klinge Biopharma and Formycon to semi-exclusively commercialize FYB203, a biosimilar candidate to Eylea (aflibercept), in Europe (excluding Italy) and Israel. This partnership builds on their successful collaboration with Formycon’s biosimilar FYB201 to Lucentis (ranibizumab) in Europe. The agreement strengthens Teva's biosimilars portfolio and aligns with its Pivot to Growth strategy, combining Teva’s commercial expertise with Formycon’s development capabilities. Klinge holds the exclusive global commercialization rights for FYB203.
October 2024: Teva Pharmaceuticals and mAbxience expanded their strategic partnership to include the development of an additional oncology biosimilar candidate targeting anti PD-1. This new global licensing agreement marks the second collaboration between the companies, following their initial partnership in April 2024. The expanded agreement supports Teva's Pivot to Growth strategy and strengthens its biosimilar portfolio. Both companies reaffirmed their commitment to providing high-quality, affordable treatments to patients worldwide.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 100 companies operating in the Biosimilar Market market, including revenue, employee count, and market positioning where available.
Showing 100 of 100 companies
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Eli Lilly is a research-based, vertically integrated pharmaceutical manufacturer that discovers, develops, manufactures and markets prescription medicines in a single reported business segment: human pharmaceutical products. Its commercial identity has been transformed since 2022 by the incretin class: tirzepatide, a dual GIP/GLP-1 receptor agonist, and from April 2026 orforglipron, an orally bioavailable non-peptide GLP-1 agonist. These assets have made Lilly the dominant player in the fastest-growing therapeutic category in pharmaceutical history, and have funded a step-change in capital deployment — more than $50 billion of announced U.S. manufacturing investment since 2020, $13.3 billion of FY2025 R&D spend, and more than a dozen acquisitions in 2026 alone. Around that core the company sustains four other franchises — oncology, immunology, neuroscience and legacy diabetes — and a direct-to-patient platform, LillyDirect. Lilly's central strategic bet is that obesity becomes a chronic-care category of unprecedented scale, and that it can own the supply, the pricing architecture and the next three generations of molecules within it. Eli Lilly and Company is, as of September 2026, the largest pharmaceutical company in the world by market capitalisation and the fastest-growing large-cap drug manufacturer by revenue. The company crossed the $1 trillion market-capitalisation threshold during 2025 — the first biopharmaceutical company ever to do so — on the strength of a single molecule, tirzepatide, commercialised under two brands (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnoea) that together generated $36.5 billion of revenue in FY2025. In April 2026 the company added the first small-molecule oral GLP-1 receptor agonist approved for obesity, Foundayo (orforglipron), to that franchise. --- ### The company's own characterisation Lilly describes itself in the FY2025 Form 10-K as a company that discovers, develops, manufactures and markets products in a single business segment — human pharmaceutical products — and states that most of the products it sells today were discovered or developed by its own scientists, with long-term success depending on the ability to continually discover or acquire, develop and commercialise innovative medicines. It manufactures and distributes through facilities in the United States (including Puerto Rico) and in Europe and Asia, and sells in approximately 105 countries. In its standard corporate boilerplate (Q2 2026 earnings release) Lilly positions itself as "a medicine company turning science into healing," with a 150-year history and scientific focus areas described as redefining diabetes care; treating obesity and curtailing its long-term complications; advancing the fight against Alzheimer's disease; addressing immune system disorders; and transforming difficult-to-treat cancers into manageable diseases. ### Independent characterisation Lilly is best understood today as three overlapping businesses operating under one P&L: **(a) The incretin platform (roughly 74% of FY2025 revenue).** Tirzepatide (Mounjaro + Zepbound) alone contributed $36.5 billion in FY2025, growing to a first-half 2026 run-rate of $27.7 billion across the two brands. Adding orforglipron (Foundayo, $98 million in its first partial quarter), legacy insulins, Trulicity and the Boehringer-partnered SGLT2/DPP-4 products, cardiometabolic health accounted for approximately $48.2 billion of FY2025 revenue. This is a volume business with unusually strong operating leverage: gross margin on the incretin portfolio has driven consolidated gross margin from 75.4% in FY2021 to 86.3% (non-GAAP) in Q2 2026, even as realised prices fell 13% year-on-year in that quarter. **(b) The diversified specialty portfolio (roughly 24% of FY2025 revenue).** Oncology ($9.4 billion), immunology ($5.2 billion) and neuroscience ($1.4 billion) constitute a conventional branded-pharma business with a normal mix of growth assets (Jaypirca, Ebglyss, Omvoh, Kisunla, Inluriyo) and mature or declining ones (Cyramza, Emgality, Taltz, Olumiant). Management has explicitly flagged this cluster as its diversification hedge: key-product revenue in immunology, oncology and neuroscience grew 121% year-on-year in Q2 2026. **(c) A capital-deployment engine.** With $16.8 billion of FY2025 operating cash flow rising to a $28.1 billion trailing-twelve-month figure at June 2026, Lilly has become one of the most acquisitive companies in the sector — at least thirteen acquisitions announced in 2026 through August — and the largest single builder of pharmaceutical manufacturing capacity in U.S. history. ### Revenue model and value-chain position Lilly's revenue is overwhelmingly product revenue. Approximately 93.5% of FY2025 revenue was product sales, with the balance (approximately $4.2 billion) collaboration and other revenue, principally from the Boehringer Ingelheim diabetes alliance, the Incyte relationship on Olumiant, royalty streams and sales-based milestones. There is no subscription revenue; "service" revenue is immaterial. The company occupies an unusually deep position in its value chain for a modern large-cap pharma: it manufactures its own active pharmaceutical ingredients, fills and finishes its own injectable devices, and, since January 2024, sells directly to patients through LillyDirect, bypassing parts of the traditional wholesaler-pharmacy-PBM chain for self-pay volumes. **Customer types and end-markets.** The direct customers are wholesalers and distributors (McKesson, Cencora, Cardinal Health in the U.S.), retail and specialty pharmacy chains, hospital systems, government purchasers (Medicare Part D plans, Medicaid programs, the Veterans Health Administration, and from 2026 the TrumpRx platform), managed-care organisations and pharmacy benefit managers, and — increasingly — patients paying cash through LillyDirect and affiliated telehealth partners. End-markets are obesity and metabolic disease, type 2 diabetes, oncology, immunology/inflammation, neurodegeneration and pain.
Sanofi is a top-tier global biopharmaceutical company that has, over six years, deliberately narrowed itself from a diversified healthcare conglomerate into a single-segment, R&D-led specialty medicines and vaccines business. Its centre of gravity is immunology: Dupixent, co-developed with Regeneron, generated €15.7bn in FY2025 — 36% of group sales — and management now guides to approximately €25bn by 2030. Around that core sit a differentiated rare-disease franchise (Pompe, Gaucher, Fabry, haemophilia, ASMD), the world's broadest vaccines portfolio outside Merck and GSK, and a smaller oncology and neurology presence. The company shed EUROAPI in 2022 and sold control of Opella consumer health to CD&R in 2025 for €10.4bn net. Financially it is unusually clean — 77.5% business gross margin, 0.8x net debt/EBITDA, 31 consecutive years of dividend increases. The unresolved question, and the reason for a February 2026 CEO change, is whether its internal pipeline can replace Dupixent's eventual erosion. *Caveat: Sanofi does not publish a single headline headcount in its quarterly releases. The FY2021 figure derives from the company's 2022 employee share plan disclosure ("over 90,000 employees in 73 countries" eligible in 2021); the FY2024/FY2025 figure of ~83,000 is the company-sourced number cited in industry reporting at the time of the March 2025 US investment announcement, reflecting both restructuring and the Opella separation. Precise year-end FTE counts are disclosed in the Universal Registration Document / Form 20-F and are not restated here. The 2025 employee share plan was offered to "around 70,000 employees in 55 countries" — an eligibility population, not total headcount.* --- ### What Sanofi does Sanofi researches, develops, manufactures and commercialises prescription medicines and human vaccines. Since January 1, 2025 it reports one operating segment, Biopharma, plus an immaterial "Other" line that captures residual Opella-related transitional revenues and manufacturing services. Sanofi's own characterisation, used verbatim in every 2026 press release, is: *"Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world."* The formal segment description in its 2025 shelf-registration prospectus reads: *"We have one operating segment: Biopharma. It comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories."* Internally, and in the reporting taxonomy adopted from FY2025, the business is organised as: - **Pharma** - *Immunology* — Dupixent, Kevzara - *Rare diseases* — Fabrazyme, Cerezyme/Cerdelga, Myozyme/Nexviazyme, Aldurazyme, Xenpozyme, ALTUVIIIO, Eloctate, Alprolix, Cablivi, Qfitlia, Wayrilz, Ayvakit - *Neurology* — Aubagio (in run-off), Cenrifki (tolebrutinib) - *Oncology* — Sarclisa, Jevtana, Fasturtec - *Other main / established medicines* — Lantus, Toujeo, Apidra, Soliqua, Plavix, Lovenox, Aprovel, Multaq, Praluent, Thymoglobulin, Rezurock, Synvisc - **Vaccines** — influenza (Fluzone/Efluelda/Vaxigrip), polio/pertussis/Hib (Pentacel, Pentaxim, Hexaxim, Vaxelis via JV), meningitis (Menactra, MenQuadfi), travel/endemic (rabies, yellow fever, typhoid, hepatitis A), Beyfortus (RSV mAb, with AstraZeneca), Nuvaxovid (COVID-19), Heplisav-B (adult hepatitis B, acquired with Dynavax) ### Revenue model Sanofi's revenue is overwhelmingly product sales of patented and off-patent pharmaceuticals and vaccines — there is effectively no subscription or service revenue. The economics have four distinct layers: 1. **Net sales (€43,626m FY2025)** — gross invoiced product sales less gross-to-net deductions (US rebates, Medicaid/340B, chargebacks, ex-US statutory price cuts, China VBP/NRDL). 2. **Other revenues (€3,090m FY2025)** — a materially different-margin stream comprising VaxServe's distribution of *non-Sanofi* vaccines in the US (€1,780m FY2025, declining), manufacturing services (€557m), transitional sales of Opella products in certain markets (€487m), and royalties (€146m). 3. **Alliance profit-sharing, recorded in other operating income/expenses** — this is the single most important non-obvious feature of Sanofi's P&L. Sanofi books 100% of worldwide Dupixent and Kevzara sales but must then pay Regeneron its share of alliance profit. In FY2025 the total charge related to Regeneron was €4,923m, of which €5,065m was the monoclonal-antibody alliance net (profit/loss share −€5,455m, plus €1,089m of Regeneron's contribution to development costs, less €699m reimbursement of Regeneron commercial operating expenses). This charge grew 28% year-on-year and structurally caps Sanofi's operating leverage on its fastest-growing asset. 4. **Out-licensing royalties** — notably the Amvuttra royalty (€398m in H1 2026, up from €120m in H1 2025) and other license-out income (€495m FY2025). ### Value chain position and customers Sanofi is a fully integrated originator: discovery research, clinical development, regulatory, primary and secondary manufacturing (biologics, sterile injectables, vaccine bulk and fill-finish), and direct commercialisation in most markets. It also operates VaxServe, a US vaccine and specialty-pharmaceutical distribution business that carries third-party product — a rare downstream extension. Customers are institutional rather than retail: US wholesalers (McKesson, Cencora, Cardinal) and PBMs, national and regional health systems and tender authorities in Europe, public immunisation programmes and supranational buyers (UNICEF, PAHO, Gavi) for vaccines, hospital groups, and specialty pharmacies for rare disease and biologic products. End-markets are immunology and inflammation, rare genetic disease, haematology, multiple sclerosis, multiple myeloma, diabetes, cardiovascular disease, and paediatric and adult immunisation. ### Independent characterisation Functionally Sanofi is now one very large product (Dupixent) plus a durable but low-growth annuity book plus an option on a rebuilt pipeline. Dupixent contributed 36% of FY2025 net sales and 44.4% of Q2 2026 net sales, and grew 37.6% in Q2 2026 — meaning group growth is almost entirely one franchise. The vaccines business, historically Sanofi's defensive ballast, has become a source of volatility: it declined 1.2% in FY2025 and 1.1% in H1 2026, pressured by falling birth rates in China, US immunisation-policy uncertainty, and competitive tendering. The rare-disease and haemophilia portfolios are genuinely differentiated but individually sub-scale. The strategic problem management is now addressing is that Sanofi has bought growth (Blueprint, Dynavax, Vicebio) faster than it has generated it internally — and in July 2026 discontinued three of the assets that were supposed to be the answer.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Company Headquarters: New York, US Founded: 2003 Workforce: ~150 Company Working: Cleveland Biolabs, Inc. is an innovative biopharmaceutical company developing products to address immune system diseases and serious medical needs. It is specialized in offering products such as radiation injury products, immune-oncology, and orphan drugs. It has nine product candidates in its pipeline that have been developing directly through itself or its wholly owned companies, namely Incuron, LLC (US) and Panacela Labs, Inc. (US). It has a proprietary platform, namely the Advanced Immunomodulating Multi-Receptor System (AIMS) platform, which is designed to restore immune homeostasis. Moreover, it has collaboration with government agencies which supports the advanced development and procurement of new medical countermeasures including drugs, vaccines, diagnostics, and medical supplies in order to protect public health from chemical, biological, radiological, and nuclear threats.
24 interactive charts drawn from the Biosimilar Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Biosimilar Market By Region
Global Biosimilar Market By Specialty Pharmacies
Global Biosimilar Market By Online Pharmacies
Global Biosimilar Market By Retail Pharmacies
Global Biosimilar Market By Hospital Pharmacies
Global Biosimilar Market By Intravenous
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
